Genprex, Inc. (GNPX) Stock Price & Analysis
Genprex, Inc. (GNPX) rose 2.14% to USD 3.58 as of September 8, 2026 at 16:20 UTC, according to Nexqual real-time market data.
GNPX last closed at USD 3.58; the session ranged USD 3.44–3.65 on volume of 17,361 shares. Market capitalization is —, with a 52-week range of USD 3.37–1,210 (NCM). Source: Nexqual, September 8, 2026 at 16:20 UTC.
Key Statistics (as of September 8, 2026 at 16:20 UTC)
| Price | USD 3.58 |
|---|---|
| Change | ▲ 2.14% (up) |
| Previous Close | USD 3.58 |
| Open | USD 3.58 |
| Day Range | USD 3.44 – 3.65 |
| 52-Week Range | USD 3.37 – 1,210 |
| Volume | 17,361 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (GNPX)
Nexqual's technical model rates GNPX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 16:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.1 (oversold) |
| vs SMA50 | Below (USD 6.77) |
| MACD | -0.88 (negative) |
From Genprex, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.   Oncology Platform   Our lead oncology drug candidate, REQORSA® Gene Therapy (generic name: quaratusugene ozeplasmid ), previously referred to as GPX-001, is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer ("NSCLC") and Small Cell Lung Cancer ("SCLC").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CODX | Co-Diagnostics, Inc. | USD 1.14 | ▼ 1.72% |
| DARE | Dare Bioscience, Inc. | USD 0.71 | ▼ 0.28% |
| AIM | AIM ImmunoTech Inc. | USD 0.23 | ▲ 1.57% |
| NNVC | NanoViricides, Inc. | USD 1.11 | ▼ 3.48% |
| AYTU | Aytu BioPharma, Inc. | USD 2.23 | ▼ 2.84% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 16:20 UTC. This page is informational and not investment advice.